{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT04108195","nct_id":"NCT04108195","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04108195. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.","label":"Part 1: Dose Escalation","type":"EXPERIMENTAL"},{"description":"Participants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1.","label":"Part 2: Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":290,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Daratumumab","otherNames":["JNJ-54767414, Darzalex"],"type":"DRUG"},{"name":"Talquetamab","otherNames":["JNJ-64407564"],"type":"DRUG"},{"name":"Teclistamab","otherNames":["JNJ-64007957"],"type":"DRUG"},{"name":"Pomalidomide","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-04-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1: Number of Participants With Dose Limiting Toxicity (DLT)","timeFrame":"Up to 52 Weeks"},{"measure":"Part 1: Number of Participants With Dose Limiting Toxicity by Severity","timeFrame":"Up to 52 Weeks"},{"measure":"Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to 48 Weeks"},{"measure":"Part 2: Number of Participants With Adverse Events and SAEs by Severity","timeFrame":"Up to 48 Weeks"}],"references":[{"citation":"Rodriguez-Otero P, Morillo D, D'Souza A, Reece D, van de Donk N, Chari A, Dholaria B, Kortum KM, Mateos MV, Mckay JT, Rosinol L, Sureda A, Wasch R, Bhutani M, Weisel KC, Bahlis NJ, Vishwamitra D, Skerget S, Bakshi KK, Guo Y, Sun W, Goldberg JD, Stephenson T, Prior TJ, Vandenberk L, Lee S, Smit MD, Verona RI, Oriol A, Krishnan A. Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study. Blood Adv. 2026 Sep 2:bloodadvances.2026020648. doi: 10.1182/bloodadvances.2026020648. Online ahead of print.","pmid":"42685673","type":"DERIVED"},{"citation":"Chari A, van de Donk NWCJ, Dholaria B, Weisel K, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodriguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosinol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi K, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit MD, Wasch R. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025 Dec 11;146(24):2902-2913. doi: 10.1182/blood.2025029360.","pmid":"40983036","type":"DERIVED"},{"citation":"Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, Zhang X, Mendonca M, Majewski N, Nanjunda R, Chin D, Packman K, Elsayed Y, Attar R, Gaudet F. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549. doi: 10.1182/bloodadvances.2020002393.","pmid":"32956453","type":"DERIVED"}],"start_date":{"date":"2020-02-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT04108195"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04108195"}